基本信息
浏览量:150

个人简介
His laboratory research focuses on the biology of immune inhibitory receptors including leukocyte Ig-like receptor subfamily B (LILRB) in cancer immunology and hematopoietic cells. He is also accustomed to working at the intersection of basic research and its clinical applications; anti-LILRB2 and anti-LILRB4 blocking antibodies discovered by his team/collaborators are in clinical trials for treatment of myeloid leukemia and solid cancers. He published 119 peer-reviewed publications in hematopoietic and cancer research fields. He was a recipient of several awards, including American Society of Hematology Junior Faculty Scholar Award, Leukemia & Lymphoma Society Scholar Award, and Royan International Research Award. He has trained 8 graduate students and 27 post-doctoral researchers. Many of his former postdoc trainees acquired faculty positions.
研究兴趣
论文共 54 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Yubo He,Chengcheng Zhang, Lingxiao Tan,Mi Deng, Xiaoye Liu, Ryan Huang, Xing Yang,Jingjing Xie, Qi Lou, Meng Fang, Caroline Smith, Samuel John, Wei Xiong, Xin Li,Cheryl Lewis,Jade Homsi, Ankit Gupta,Ningyan Zhang,Zhiqiang An, Cheng
Cancer immunology researchno. 6 (2025): 821-835
Research square (2024)
Antibody Therapeuticsno. 2 (2024): 157-163
Nucleic Acids Research (2024)
crossref(2023)
ANTIBODY THERAPEUTICSno. 1 (2023): 13-27
Ryan Huang,Xiaoye Liu,Jaehyup Kim,Hui Deng,Mi Deng,Xun Gui,Heyu Chen,Guojin Wu,Wei Xiong,Jingjing Xie,Cheryl Lewis,Jade Homsi, Xing Yang,Chengcheng Zhang,Yubo He, Qi Lou, Caroline Smith,Samuel John,Ningyan Zhang,Zhiqiang An, Cheng
Cancer Immunology Researchno. 3 (2023): 350-362
Cancer Researchno. 12_Supplement (2022): 601-601
加载更多
作者统计
#Papers: 54
#Citation: 1485
H-Index: 21
G-Index: 36
Sociability: 5
Diversity: 2
Activity: 9
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn